Skip to content

Study · Systematic review · n = 13,662 · 2019

6 results

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.

Zhao X, Huang K, Zheng M, Duan J

BMC endocrine disorders7 Jan 2019Cited by 36 (Europe PMC)

PMID30616638 (opens in a new tab)PMCIDPMC6323665 (opens in a new tab)DOI10.1186/s12902-018-0332-5 (opens in a new tab)PepBankPUB-30616638
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundSeveral clinical trials have studied the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycometabolism and cardiovascular risk factors since they were identified. Because of their cardiovascular benefits and efficacy in lowering glucose, GLP-1RAs are becoming increasingly important in clinical therapy for patients with or without pathoglycaemia. The aim of this study was to assess the effect of the GLP-1RA liraglutide on blood pressure based on randomised controlled trials (RCTs).MethodsWe searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia. RCTs in humans that included data describing blood pressure changes from baseline to the end of the trial were selected for inclusion in the meta-analysis.ResultsA total of 18 RCTs that enrolled 7616 individuals in the liraglutide group and 6046 individuals in the control group were included in this meta-analysis. Compared with placebo, liraglutide reduced systolic blood pressure (SBP) by 3.18 mmHg (95% CI -4.32, - 2.05), P < 0.00001, but had no significant effect on diastolic blood pressure (DBP). Subgroup analysis showed that the degree of reduction in SBP was associated with the dose of liraglutide but that significance disappeared when the intervention lasted over 1 year. Liraglutide 3.0 mg/d significantly reduced DBP by 1.46 mmHg (95% CI -2.61, 0.32), P = 0.01, but liraglutide 1.8 mg/d slightly increased DBP by 0.47 mmHg (95% CI 0.11, 0.83), P = 0.01, compared with placebo.ConclusionsThis meta-analysis demonstrated that liraglutide significantly reduced SBP in individuals with or without pathoglycaemia compared with placebo, but the difference was no longer significant when the intervention lasted over 1 year. Moreover, the effect of liraglutide on blood pressure is associated with the dose. This finding may provide additional evidence for cardiovascular protection.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of RCTs, liraglutide reduced systolic blood pressure by 3.18 mmHg compared with placebo.

    In plain wordsIn trial participants, liraglutide lowered systolic blood pressure by about 3 mmHg more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 13,662

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    SBP reduction
    3.18 mmHg
    liraglutide vs placebo

    Source sentences

    Summary
    Compared with placebo, liraglutide reduced systolic blood pressure (SBP) by 3.18 mmHg (95% CI -4.32, - 2.05), P < 0.00001, but had no significant effect on diastolic blood pressure (DBP).
    1 context sentence
    Summary · context
    We searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of RCTs, liraglutide had no significant effect on diastolic blood pressure compared with placebo.

    In plain wordsIn trial participants, liraglutide did not change diastolic blood pressure significantly compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeDiastolic blood pressure
    Study

    n = 13,662

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but had no significant effect on diastolic blood pressure (DBP).
    1 context sentence
    Summary · context
    We searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia.
  3. 03HumanSystematic reviewEfficacy outcome

    In trials lasting over 1 year, the systolic blood pressure reduction with liraglutide was no longer significant compared with placebo.

    In plain wordsIn trials longer than one year, the blood pressure drop with liraglutide was no longer significant compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSystolic blood pressure in trials longer than 1 year
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · over 1 yearAs given in this study (human).

    Source sentences

    Summary
    This meta-analysis demonstrated that liraglutide significantly reduced SBP in individuals with or without pathoglycaemia compared with placebo, but the difference was no longer significant when the intervention lasted over 1 year.
    1 context sentence
    Summary · context
    We searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of RCTs, liraglutide 3.0 mg/d significantly reduced diastolic blood pressure by 1.46 mmHg compared with placebo.

    In plain wordsIn trial participants, liraglutide at the higher 3.0 mg daily dose lowered diastolic blood pressure by 1.46 mmHg more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseDiastolic blood pressure with liraglutide 3.0 mg/d
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    3.0 mg/dAs given in this study (human).

    Measurements

    DBP reduction
    1.46 mmHg
    liraglutide 3.0 mg/d vs placebo

    Source sentences

    Summary
    Liraglutide 3.0 mg/d significantly reduced DBP by 1.46 mmHg (95% CI -2.61, 0.32), P = 0.01
    1 context sentence
    Summary · context
    We searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia.
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of RCTs, liraglutide 1.8 mg/d slightly increased diastolic blood pressure by 0.47 mmHg compared with placebo.

    In plain wordsIn trial participants, liraglutide at 1.8 mg daily slightly raised diastolic blood pressure, by 0.47 mmHg, compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseDiastolic blood pressure with liraglutide 1.8 mg/d
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.8 mg/dAs given in this study (human).

    Measurements

    DBP increase
    0.47 mmHg
    liraglutide 1.8 mg/d vs placebo

    Source sentences

    Summary
    liraglutide 1.8 mg/d slightly increased DBP by 0.47 mmHg (95% CI 0.11, 0.83), P = 0.01, compared with placebo.
    1 context sentence
    Summary · context
    We searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia.
  6. 06HumanSystematic reviewEfficacy outcome

    In a subgroup analysis of RCTs, the degree of systolic blood pressure reduction with liraglutide was associated with the dose of liraglutide.

    In plain wordsIn trial participants, how much liraglutide lowered systolic blood pressure was linked to the dose used.

    Peptide
    Liraglutide
    Outcome
    Not applicableSystolic blood pressure reduction by liraglutide dose
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Subgroup analysis showed that the degree of reduction in SBP was associated with the dose of liraglutide
    1 context sentence
    Summary · context
    We searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.